Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 25 (3), 673-5

Patients With High-Bone-Mass Phenotype Owing to Lrp5-T253I Mutation Have Low Plasma Levels of Serotonin

Affiliations

Patients With High-Bone-Mass Phenotype Owing to Lrp5-T253I Mutation Have Low Plasma Levels of Serotonin

Morten Frost et al. J Bone Miner Res.

Erratum in

  • J Bone Miner Res. 2010 Aug;25(8):1896

Abstract

The Lrp5 gene is a major determinant of bone mass accrual. It has been demonstrated recently to achieve this function by hampering the synthesis of gut-derived serotonin, which is a powerful inhibitor of bone formation. In this study we analyzed plasma serotonin levels in patients with a high-bone-mass (HBM) phenotype owing to gain-of-function mutation of Lrp5 (T253I). A total of 9 HBM patients were compared with 18 sex- and age-matched controls. In HBM patients, the serotonin concentrations in platelet-poor plasma were significantly lower than in the controls (mean +/- SEM: 2.16 +/- 0.28 ng/mL versus 3.51 +/- 0.49 ng/mL, respectively, p < .05). Our data support the hypothesis that circulating serotonin levels mediate the increased bone mass resulting from gain-of-function mutations in Lrp5 in humans.

Similar articles

See all similar articles

Cited by 18 articles

See all "Cited by" articles

Publication types

Substances

Feedback